221 related articles for article (PubMed ID: 33486650)
21. Management of recurrent venous thromboembolism in patients with cancer: A review.
Piran S; Schulman S
Thromb Res; 2018 Apr; 164 Suppl 1():S172-S177. PubMed ID: 29703478
[TBL] [Abstract][Full Text] [Related]
22. Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism.
Delate T; Charlu M; Zhu S; Pai A; Clark NP; Witt DM; King JM; King JB
Thromb Res; 2020 Dec; 196():367-370. PubMed ID: 32979674
[TBL] [Abstract][Full Text] [Related]
23. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures.
Tiryaki F; Nutescu EA; Hennenfent JA; Karageanes AM; Koesterer LJ; Lambert BL; Schumock GT
Am J Health Syst Pharm; 2011 Jul; 68(13):1239-44. PubMed ID: 21690430
[TBL] [Abstract][Full Text] [Related]
25. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
27. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
29. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
[TBL] [Abstract][Full Text] [Related]
30. Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy.
Nakamura M; Yamada N; Ito M
J Cardiol; 2015 Dec; 66(6):451-9. PubMed ID: 25896176
[TBL] [Abstract][Full Text] [Related]
31. Apixaban: A Review in Venous Thromboembolism.
Greig SL; Garnock-Jones KP
Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
[TBL] [Abstract][Full Text] [Related]
32. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
33. [Optimal duration of anticoagulation of venous thromboembolism].
Savina EN; Couturaud F
J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
[TBL] [Abstract][Full Text] [Related]
34. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.
Lecumberri R; Alfonso A; Jiménez D; Fernández Capitán C; Prandoni P; Wells PS; Vidal G; Barillari G; Monreal M;
Thromb Haemost; 2013 Oct; 110(4):834-43. PubMed ID: 23846721
[TBL] [Abstract][Full Text] [Related]
36. Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-term Treatment.
Agrawal V; Kim ESH
Curr Cardiol Rep; 2019 Mar; 21(4):24. PubMed ID: 30828779
[TBL] [Abstract][Full Text] [Related]
37. Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis.
Ratté MT; Jones AE; Witt DM; Young DC
Pediatr Pulmonol; 2020 Jan; 55(1):149-155. PubMed ID: 31502767
[TBL] [Abstract][Full Text] [Related]
38. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
39. Direct Oral Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism in Routine Clinical Practice.
Ogino Y; Ishigami T; Minamimoto Y; Kimura Y; Akiyama E; Okada K; Matsuzawa Y; Maejima N; Iwahashi N; Hibi K; Kosuge M; Ebina T; Ishikawa T; Tamura K; Kimura K
Circ J; 2020 Jul; 84(8):1330-1338. PubMed ID: 32624519
[TBL] [Abstract][Full Text] [Related]
40. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
